BACKGROUND AND AIM: Ursodeoxycholic acid (UDCA) is first-line therapy for primary biliary cholangitis (PBC), evidence for dose reduction after biochemical remission remains limited. This study aimed to evaluate the feasibility and safety of UDCA reduction in PBC. METHODS: In this open-label randomized controlled clinical trial, PBC patients who reached complete biochemical response (Paris-II criteria) after ≥ 6 months of standard 13-15 mg/kg/day UDCA therapy were prospectively enrolled. Eligible patients were assigned in a 1:1:1 ratio to receive either (1) continued 13-15 mg/kg/day, (2) 10 mg/kg/day, or (3) 5-mg/kg/day UDCA. The primary endpoint was biochemical relapse rate within 12 months. Secondary endpoints included changes in liver biochemistry, changes in patient-reported symptoms, and changes in GLOBE and UK-PBC scores, as well as adverse events. RESULTS: From January 2020 to March 2024, 96 patients who complied with the protocol after randomization were analyzed. Within the 12-month follow-up period, the relapse rates in the three groups were 0%, 2.9%, and 19.4%, respectively (overall p = 0.008). Secondary outcomes showed no significant intergroup differences. In patients with a disease relapse, prompt retreatment with a standard dose of UDCA could help liver function recover. No severe adverse events were observed. CONCLUSIONS: The relapse rate in the 5-mg/kg/day group was significantly higher than that in the standard-dose group, necessitating close clinical monitoring, and no significant difference in relapse was observed between the 10 mg/kg/day and standard-dose group, suggesting it may be a potential dose-reduction strategy, though further studies are needed for confirmation.
He et al. (Tue,) studied this question.